Cannabis for Drug Resistant Epilepsy
|
|
- Allen Reed
- 5 years ago
- Views:
Transcription
1 Cannabis for Drug Resistant Epilepsy MILA SORIN, MD PEDIATRIC NEUROLOGY APRIL 20, 2018
2 Introduction -Although more than 20 prescription anti-epileptic drugs (AEDs) are available, they prove to be ineffective in approximately 25 30% of people with epilepsy -Side effects may limit available options -Other options include steroids, vagus verve stimulator, responsive electrical stimulator, ketogenic diet, surgery -Other effects of uncontrolled seizures include cognitive dysfunction, psychiatric comorbidities, behavioral problems -Proportion of patients with uncontrolled seizures has not decreased -Since 2013, Cannabidiol (CBD) has been studied in 10 epilepsy centers using Epidolex
3 History -Cannabis has been used for thousands of years for medical, religions, and recreational purposes -Most consumed illegal recreational drug worldwide -Originated in Central Asia and cultivated in China for fiber and seed production -Has been used medicinally in China dating back to 2700 BC, in India 1000BC -The first studies on medicinal use of marijuana date back to the Chinese Emperor Shen Nung -Records exist in Arabic and Islamic literature -Cannabis was used as treatment for epilepsy in Victorian times and even earlier
4 History -The first publication of cannabis for treatment of seizures was in 1843 by W.B. O Shaughnessy He tested Cannabis extract in patients with various disorders -Used in the US through the early 20 th century but halted after its criminalization in the 30s -Cultivation of the plant was made illegal in many countries -In the last few decades studies have showed CBD to have a few therapeutic benefits
5 History -In 1970 Mechoulam randomized 9 patients with refractory temporal lobe epilepsy to receive CBD or placebo for 5 weeks in addition to their seizure medication. At 3 month follow up, 2 of 4 patients receiving CBD were seizure free compared to 0 patients in the placebo group who showed no improvement -In 1975, a study by Consroe et al described a 24 year old patient with uncontrolled seizures taking phenobarbital and phenytoin who became seizure free after smoking cannabis socially -Use in the US remains restricted because of its status as a Schedule 1 controlled substance -In late 2013, the US Food and Drug Administration granted orphan drug status to an imported, pharmaceutically standardized CBD extract (Epidiolex, GW Pharmaceuticals) as an experimental treatment for pediatric epilepsy. -Clinical trials of its safety and efficacy in children with severe forms of refractory epilepsy, such as Dravet syndrome and Lennox Gastaut syndrome, began in 2014
6 Number of articles from PubMed using search items cannabis and epilepsy
7 Cannabis -Genus Cannabis is a flowering plant with 3 main species: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. -The plants have >100 biologically active chemicals called cannabinoids with the most neuro-active being CBD and THC (left). -Half life between hours
8 Cannabis sativa/indica -As more states legalize cannabis, dispensaries sell extracts of the plant in oil -Typically strains are high in cannabidiol (CBD) and low in tetrahydrocannabinol (THC) -Marijuana is typically high in THC which is unsuitable for the treatment of epilepsy because of the many undesired effects -compared to THC, CBD shows anticonvulsant effects in animal models
9 Mechanism of Action -The endogenous cannabinoid system (ECS) is a neuromodulatory system that consists of lipid-like signaling molecules, endocannabinoids, (ECs) that interact with cannabinoid CB1 and CB2 receptors and two endogenous ligands, 2- arachidonoylglycerol (2-AG) and anandamide CB1 receptors are primarily located in neurons while CB2 receptors are primarily located in microglia and some in the immune system CB1 receptors are pre-synaptic in both glutamatergic and GABAergic interneurons, and activation of which results in inhibition of synaptic transmission including glutamate release CB1 receptors mediate neuronal inhibition by decreasing calcium influx and increasing potassium efflux in presynaptic terminals
10 Mechanism of Action -ECS plays a major role in regulating neuronal excitability, neuroinflammation, and excitotoxicity within the brain -Pharmacological and genetic modulation of the ECS in rodents causes major effects on seizure susceptibility -CBD changes the metabolism of other epilepsy medications such as clobazam, causing their levels to rise.
11 Mechanism of Action -THC acts as a partial agonist of CB1 and CB2 receptors -CBD has little affinity for CB1 and CB2 receptors but antagonizes CB1/CB2 receptor agonists -CBD also activates 5-HT serotonergic receptors, antagonizes alpha-1 adrenergic receptors and mu-opioid receptors, inhibits uptake of adenosine, dopamine noradrenaline -CBD reduces oxidative damage, T cell responses, TNF release, production of prostaglandin E2, reduces production of nitric oxide and cyclooxygenase
12 CBD -highly bound to proteins (>99%) -extensively metabolized by cytochrome P450 -enzyme inducing AEDs such as carbamazepine and phenytoin can accelerate CBD metabolism and reduce CBD levels -reinforces sedating effects of other psychotropic substances such as benzodiazepines and alcohol -In one study of 13 patients taking Clobazam, addition of CBD of initial dose of 5mg/kg/day titrated to 25mg/kg/day resulted in increase of clobazam levels by 60% at 4 weeks This interaction is thought to be mediated by inhibition of CYP2c19 -highly lipophilic so distributes extensively into tissues resulting in late-phase half-life of about 24 hours
13 Lennox-Gastaut Syndrome -may be caused by brain malformations, head injury, CNS infections, metabolic disorders, inherited degenerative disorders -onset typically before age 4 -patients have uncontrolled seizures of various types -nearly all patients are refractory to medications -most children have intellectual disability, developmental delay, and behavioral problems
14 Dravet Syndrome -severe myoclonic epilepsy of infancy -onset in infancy, often starts with prolonged febrile seizures, then progresses to other seizure types with myoclonic, alternating hemi-convulsions, heat sensitive. ~80-90% associated with SCN1A mutation -nearly all patients are refractory to medications -nearly all children have developmental delay
15 Clinical Trials -CBD was added to baseline AEDs at an initial dose of 2-5mg/kg/day divided bid -CBD was titrated by 2-5mg/kg/week until 25mg/kg/day or until intolerance -No objective testing in most studies -Most are open label, uncontrolled or surveys -Many relied on parental response bias
16 C.A. Press, K.G. Knupp, K.E. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav, 45 (2015), pp Study in Colorado reported 22% responder rate for patients originally from Colorado compared to 47% for patients that moved to Colorado, suggesting reporter bias
17
18 Drawbacks -CBD is appealing but untested and unregulated -concentration can vary based on plant, weather, soil, and other factors -Studies are mainly retrospective and based on patient or parental reportestimates of efficacy -Some marketed products when tested have been found to have different content of CBD than stated in their label, and some may have harmful contaminants -Preferential use in CBD containing oil or liquid extracts
19 Strain to strain consistency? State CBD concentration mg/ml Price range (US$/mg CBD) Arizona California Colorado New Jersey Tennessee Washington Manufacturer recommended dose (mg
20 Retrospective study at Vanderbilt University Medical Center from January 2006-December pediatric patients took CBD oil for epilepsy -33% had >50% reduction in seizure frequency -10% of patients achieved seizure freedom -4% had increase in seizure frequency -Duration of treatment was 1.1 years compared to 2.5 years of Clobazam -most common reason for stopping CBD was lack of benefit, 1% with dizziness, 1% with nausea -positive side effects include 9% with improved alertness, 5% more verbal, 3% with better social interaction, 2% with better mood, 2% with decreased aggression -exact dose was not documented and CBD was obtained from 10 different vendors
21 Cunha, J. et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, patients ages with intractable temporal lobe epilepsy -Patients were enrolled in a double blind placebo controlled study with 8 patients receiving CBD for 8-18 weeks and 7 patients receiving placebo -4/8 patients receiving CBC had significant improvement in seizures with almost full control of their seizures throughout the study -3/8 patients receiving CBD had partial improvement in seizures, the other 1 patient showed no improvement -3/8 patients receiving CBD showed improvement in their EEG -1/7 patients receiving placebo showed improvement in their seizures
22 Devinsky O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial -214 patients aged 1-30 with intractable childhood-onset epilepsy -20% patients had Dravet syndrome and 19% of patients had Lennox- Gastaut syndrome -patients received oral cannabidiol 2-5mg/kg/day up to 50mg/kg -162 patients achieved 12 weeks of follow up -adverse events reported in 79% patients: somnolence in 25%, decreased appetite in 19%, diarrhea in 19%, fatigue in 13%, convulsions in 11%, status epilepticus in 6%
23 Devinsky study continued.. -Assessment of efficacy was performed in a subgroup of 137 patients, excluding patients with less than 12 week follow up median reduction in seizures was 36.5% (43% for Dravet patients and 36% for Lennox-Gastaut syndrome patients) 7% of patients became seizure free 50% of patients had 50% or more reduction in motor seizures if also taking clobazam compared to 27% not taking clobazam Patients taking clobazam experienced more side effects, mostly somnolence
24 Treat L. et al. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. -retrospective chart review of 119 pediatric patients in Colorado that used oral cannabis extracts (OCE) for treatment of epilepsy -24% had >50% reduction in seizures -71% terminated use of OCE product -19% reported adverse events with most common being somnolence (6%) and worsening seizures (8%) this is much lower than Devinsky study (79%) which may be due to high dosing parameters in the Devinsky trial -39% reported improved behavior/alertness, 8% reported improved motor skills, 7% reported improved sleep -relocation to Colorado was associated with perceived benefit (65% vs 35%)
25 Tzadok M, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure Feb; 35(): Study done in Israel in 74 pediatric patients with refractory epilepsy who mostly had epileptic encephalopathies, 90% with cognitive impairment -Patients were treated with CBD oil (CBD:THC ratio 20:1) of 1-20mg/kg/day -unlike other studies, CBD oil was prescribed by a physician -50% of patients reported at least 50% reduction in seizures-many patients reported improvement in alertness, behavior, language, communication, motor skills, and sleep -45% of patients reported side effects including somnolence (22%), seizure aggravation (18%), GI symptoms and irritability (7%)
26 Devinsky et al. Cannabidiol in Dravet Syndrome Study Group.N Engl J Med double blind study of 23 centers in US and Europe of 120 patients with Dravet syndrome ages 2-18 randomized to receive placebo or CBD 20 mg/kg/day divided bid -duration of treatment was 14 days which included a 2 week titration time -median reduction in monthly seizure frequency was 39% in the CBD group compared to 13% in the placebo group -5% of patients became seizure free in the CBD group compared to none in the placebo group -limitation of the study was 65% of patients were also taking clobazam -Side effects were reported in 75% of patients in the CBD group compared to 36% in the placebo group. Somnolence (36%), diarrhea (31%), decreased appetite (28%), fatigue (20%), worsening seizures (11%) 18/22 who developed somnolence were co-treated with clobazam 8 patients discontinued the trial prematurely in the CBD group due to side effects compared to 1 patient in the placebo group
27 Mazurkiewicz-Beldzinska M, et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). 32nd International Epilepsy Congress; 2017 Sep 2 Sep 6; Barcelona, Spain Epilepsia. In press -double blind controlled study of 171 patients with Lennox-Gastaut syndrome, with uncontrolled drop seizures randomized to receive CBD 20 mg/kg/day vs placebo for 14 weeks -14 patients in the CBD group and 1 patient in the placebo group withdrew from the study due to adverse events -median reduction of seizures was 44% in the CBD group compared to 24% in the placebo group -side effects were reported in 86% of patients in the CBD group compared to 69% in the placebo group, most common being somnolence, diarrhea, decreased appetite, and vomiting
28 Zuberi S et al. Cannabidiol (CBD) significantly decreases drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): Rresults of a doseranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). 32nd International Epilepsy Congress; 2017 Sep 2 Sep 6; Barcelona, Spain Epilepsia. In press -double blind controlled study of 225 patients with Lennox-Gastaut syndrome, mean age of 16, with uncontrolled seizures were randomized to three groups: CBD dose 10 mg/kg/day; CBD dose 20 mg/kg/day; Placebo -patients were taking a median of 3 anti-seizure drugs and study duration was 14 weeks -median reduction of drop seizures was 42% in the CBD 20mg/kg group, 37% in the 10mg/kg group, compared to 17% in the placebo group -94% of patients reported side effects in the CBD 20 mg/kg group, 84% in the 10 mg/kg group, and 72 % in the placebo group: somnolence and decreased appetite
29 Charlotte -little girl with Dravet syndrome (confirmed with SCN1A mutation) -experienced remarkable improvement in her seizures after switching to CBD oil
30 Porter,B. E., et al. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatmentresistant epilepsy. Epilepsy and Behavior, Survey of Facebook group dedicated to use of CBD for treatment resistant seizures -13 children had Dravet syndrome, 1 had Lennox Gastaut Syndrome, and 1 had idiopathic epilepsy -Average number of antiepileptic drugs tried was 12 -Seizure frequency ranged from 2/week to 250/day -16/19 patients had reduction in seizure frequency -2 of these reporting complete seizure freedom -8 of these reporting reduction greater than 80% in seizure frequency -6 of these reporting 25-60% reduction in seizure frequency -Other benefits included increased alertness, better mood, improved sleep -Side effects were mild including drowsiness and fatigue
31 Hess ej, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57: patient with tuberous sclerosis complex (TSC) took CBD fo 6-12 months -median total weekly seizure frequency reduced by 32% after 2 months, 55% after 6 months, and 63 after 12 months. -epileptic spasms and atonic seizures showed the greatest response -study limited by small sample size, uncontrolled design, and unblinded.
32 Conclusions -Evidence of CBD has become more prevalent in the last year with emergence of the first placebo controlled study of CBD in patients with Dravet syndrome and Lennox-Gastaut syndrome -Shows class 1 evidence that CBD improves seizure control -Limitation is that it is difficult to conclude that CBD has direct anti-seizure properties -The 2 studies of Lennox-Gastaut syndromes, proportion of patients taking clobazam was not reported
33 Conclusions -Part of the appeal of cannabis to parents is that by being a natural substance, it will cause less side effects Tetrodotoxin is a natural substance produced by fish -So far, side effects of CBD have been mostly benign -Elevated liver enzymes have been reported in a small percentage of patients co-medicated with valproate, and was reversible -Meta analysis of studies investigating long term effects of cannabis on neurocognitive performance in adults showed decreased ability to learn and remember new information
34 Future Direction -Future research should be blinded, randomized controlled trials to confirm efficacy and adverse effects -Other epilepsy syndromes should be studied -Long-term effects of CBD on the maturing brain are not available
35 References -Suraev A. et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy and Behavior. May Volume 70, Part B, Pages Porcari G. et al. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy and Behavior. Volume 80, March 2018, Pages Solis M. Cannabis for epilepsy: is there enough evidence of efficacy? The Pharmaceutical Journal. January 10. -Treat L. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. Volume 58, November Issue 1. -Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Journal of Epilepsy Research Dec; 7(2): Hausman-Kedem M. et al. Efficacy of Medical Cannabis for Treating Refractory Epilepsy in Children and Adolescents, with Emphasis on the Israel Experience. IMAJ. Volume 19. February Capasso A. Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. Open Neurol Journal. 2017; 11: Koo C. et al. Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy? Journal of Epilepsy Research Jun; 7(1):
Investigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationCannabinoids and Epilepsy. Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics
Cannabinoids and Epilepsy Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics Cannabinoids Cannabinoids= terpenophenolic compounds (give a scent) >80 in Cannabis sativa Cannabidiol
More information9/13/2017. Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section. Disclosures.
Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section Disclosures Site principal investigator of studies of cannabidiol(epidiolex) in the treatment of
More informationSubject: Cannabidiol (Epidiolex )
09-J3000-08 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 00/00/00 Next Review: 04/10/19 Subject: Cannabidiol (Epidiolex ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationMedical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.
Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center Controversies in Pain Management Conference Johnson City, TN November 13, 2015 Disclosure
More informationThe products being taken by children with epilepsy are not the equivalent of the marijuana widely used for recreational purposes.
Epilepsy Foundation of Colorado The Use of Cannabis to Treat Children with Epilepsy Updated February 2016 The use of extracts from marijuana plants (cannabis) to treat children with epilepsy has been in
More informationCannabis in the treatment of Autism:
Cannabis in the treatment of Autism: Are we ready? Deb Karhson, PhD and Lawrence Fung, MD, PhD Cannabis Anecdotal Data: Comparing Epilepsy and Autism+ Science of Cannabinoids: Endocannabinoid System Receptor
More informationResearch on Cannabis and PD: Is there any evidence?
Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES
More informationGW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters
More informationCannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
More informationEpidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1
Epidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1 Objectives To understand the epidemiology and pathophysiology of LGS
More informationFederal Law: Marijuana
Federal Law: Marijuana Marijuana is a Schedule I drug under Federal Controlled Substances Act Makes possession, usage, purchase, sale, and/or cultivation of marijuana illegal at the federal level May not
More informationEpidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
More informationCannabis Use in Epilepsy: Parent & Scientist Weighs In. Catherine Jacobson, PhD Director, Clinical Research
Cannabis Use in Epilepsy: Parent & Scientist Weighs In Catherine Jacobson, PhD Director, Clinical Research Professional Background PhD, Neuroscience, Oregon Health & Science University Post-doctoral Fellowship,
More informationCANNABIDIOL (CBD) THE BE ALL END ALL?
CANNABIDIOL (CBD) THE BE ALL END ALL? John Schaeffer, DO PMG neurology specialists Clinical associate professor Department of neurology University of Washington school of medicine CANNABIS BRIEF HISTORY
More informationSaving the Day - the Medical Mission
Saving the Day - the Medical Mission Dr Sukhvir Wright Honorary Consultant Neurologist, Birmingham Children s Hospital Research Fellow, Aston University My mission today Introduction Epilepsy Epilepsy
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationCannabis. Member of the Cannabaceae family of flowering plants (along with hops) Cannabis sativa (v. sativa, indica, afghanica, ruderalis)
Member of the Cannabaceae family of flowering plants (along with hops) sativa (v. sativa, indica, afghanica, ruderalis) Only females flowers contain high concentrations of psychoactive oils (cannabinoids)
More informationCannabidiol, Ataluren & SUDEP: Mechanisms, Therapies & Preventions. Orrin Devinsky, M.D. NYU Langone School of Medicine
Cannabidiol, Ataluren & SUDEP: Mechanisms, Therapies & Preventions Orrin Devinsky, M.D. NYU Langone School of Medicine Cannibas Cannabis sativa used in China 8000 BCE >420 compounds 80 terpeno-phenol compounds,
More informationGanaxolone as a Treatment for Drug-Resistant Epilepsy in Children
Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children ANTIEPILEPTIC DRUG and DEVICE TRIALS XIII May 13-15, 2015 Turnberry Isle Miami Hotel Gail M. Farfel, PhD Chief Development & Regulatory
More informationCannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Review Article Journal of Epilepsy Research pissn 2233-6249 / eissn 2233-6257 Emilio Perucca 1,2 1 Division of Clinical and Experimental
More informationCannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety
Cannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety The use of medical marijuana continues to be an emotionally and politically charged issue. Although cannabis oil preparations have been
More informationDuration of use of oral cannabis extract in a cohort of pediatric epilepsy patients
FULL-LENGTH ORIGINAL RESEARCH Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients *Lauren Treat, *Kevin E. Chapman, Kathryn L. Colborn, and *Kelly G. Knupp SUMMARY Lauren
More informationEpilepsy Syndromes: Where does Dravet Syndrome fit in?
Epilepsy Syndromes: Where does Dravet Syndrome fit in? Scott Demarest MD Assistant Professor, Departments of Pediatrics and Neurology University of Colorado School of Medicine Children's Hospital Colorado
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationCannabinoids: access and symptom management in cancer
Cannabinoids: access and symptom management in cancer Appetite stimulation Anecdotal reports suggest marijuana stimulates appetite AIDS/HIV dronabinol 2.5 mg bd v placebo (n=88) increase in appetite 38%
More informationEvaluation and management of drug-resistant epilepsy
Evaluation and management of drug-resistant epilepsy Fateme Jahanshahifar Supervised by: Professor Najafi INTRODUCTION 20 to 40 % of patients with epilepsy are likely to have refractory epilepsy. a substantive
More informationCANNABIS FOR THE RHEUMATOLOGIST
CANNABIS FOR THE RHEUMATOLOGIST Dr Jagtar Singh Nijjar NIHR Clinical Lecturer in Rheumatology Disclosures None 1 Overview The history of cannabis use Anecdotal use of cannabis in chronic pain The biology
More informationGuidance on the use of cannabis based products for medicinal use in children and young people with epilepsy
Guidance on the use of cannabis based products for medicinal use in children and young people with epilepsy 31 October 2018 Contents Glossary... 3 1 Introduction... 4 2 Background... 5 3 Summary of current
More informationCurious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD
Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD Speaker Disclosures We have/had no financial relationships with any commercial interests
More informationMedical Cannabis MATT WEBSTER DO, MS
Medical Cannabis MATT WEBSTER DO, MS Cannabis Sativa One of the oldest used drugs and medicinal remedies Most commonly abused illicit drug in the US There has been increasing access for medicinal MJ use
More informationNASDAQ: ZGNX Corporate Update
NASDAQ: ZGNX Corporate Update June 2016 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationBudding Therapies: Medical Cannabis and its Uses
Budding Therapies: Medical Cannabis and its Uses MARIAH CADAVOS, PHARMD & VIVIAN NGUYEN, PHARMD PGY1 PHARMACY PRACTICE RESIDENTS FEBRUARY 10, 2019 1 Disclosures & Disclaimer Both presenters have nothing
More informationHistory of Medical Cannabis in Nursing
History of Medical Cannabis in Nursing Kristen Luttenberger RN, MSN, CCRN, APNc http://marijuanapolitics.com/wp-content/uploads/2016/07/caduceus-lg.jpg https://images-na.ssl-imagesamazon.com/images/i/41gtt5pb4el._sx314_bo1,204,203,200_.jpg
More informationADVERSE EVENTS OF NEW AEDS. LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics
ADVERSE EVENTS OF NEW AEDS LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics DISCLOSURE Lionel Carmant: Grants/Research projects: Mettrum/ Zogenix Speakers bureau: UCB, Eisai, Lina Nova Off
More informationGW Pharmaceuticals plc. Investor Presentation May 2015
GW Pharmaceuticals plc Investor Presentation May 2015 Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs and assumptions
More informationCDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only
CDHA 2016 Fall Symposium Speaker Handout Files For registered attendees only Providing Care in a Marijuana Legal World Heather Rogers, BSDH heatherrdh@heatherrdh.com Objectives We will discuss some of
More informationCannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults
NIHR Innovation Observatory Evidence Briefing: June 2017 Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults NIHRIO (HSRIC) ID: 11079
More informationMedical Marihuana for Patients in the Lymphoma Setting. Speakers: Ruth Turner, RN, Con Rob Laister, PhD
Medical Marihuana for Patients in the Lymphoma Setting Speakers: Ruth Turner, RN, Con Rob Laister, PhD Medical Marihuana for Patients in the Lymhoma Setting Disclosure: No endorsement or promotion of marihuana
More informationCannabidiols & Epilepsy. Orrin Devinsky, M.D. Department of Neurology NYU Langone School of Medicine
Cannabidiols & Epilepsy Orrin Devinsky, M.D. Department of Neurology NYU Langone School of Medicine Cannibas in History Cannibas sativa? ~8,000 bce in China - rope Cultivated, used for garments, bowstrings,
More informationMedical Marijuana. 1. is a plant species, variety known as hemp. 3. Tetrahydrocannabinol is an aromatic with low water solubility.
Medical Marijuana Questions from Part 1: 1. is a plant species, variety known as hemp. a. Cannabis sativa Linnaeus b. Cannabis sativa c. Cannabis indica d. Cannabis Lemark 2. The major psychoactive compound
More informationMedical Marijuana. Navigating Medical Marijuana in Workers Compensation
Medical Marijuana Navigating Medical Marijuana in Workers Compensation Agenda Federal and State Laws Public Health Adverse Effects & Concerns Clinical Use Implications for Employers Implications for Workers
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationSteven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University
Steven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University sgkinsey@mail.wvu.edu Any opinions expressed are my own and do not reflect any official position of WVU beanpot.co
More informationJuly 15 TH, ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine
MEDICAL CANNABIS FOR NEUROLOGICAL DISEASES July 15 TH, 2017 ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine GOALS AND OBJECTIVES
More informationWhat s Hot. Thermal Ablation. Slide 1. Slide 2. Slide 3
Slide 1 Hot Topics in the World of Epilepsy Joseph I. Sirven, MD Professor and Chairman Department of Neurology 1 Slide 2 Surgery & Devices for Epilepsy Seizure Emergencies Cannabis What s Hot Slide 3
More informationInvestor Presentation
Investor Presentation 2018 GW Pharmaceuticals plc All Rights Reserved Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs
More informationEpilepsy in the Primary School Aged Child
Epilepsy in Primary School Aged Child Deepak Gill Department of Neurology and Neurosurgery The Children s Hospital at Westmead CHERI Research Forum 15 July 2005 Overview The School Age Child and Epilepsy
More informationMarijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US
Marijuana and Adolescents: Truth and Consequences Clinical Advances in Pediatrics Symposium Children s Mercy Park September 28, 2017 Disclosure Statement I have no actual or potential conflict of interest
More informationMedical Marijuana Update Chris Belletieri, DO
Dr. Belletieri has provided no disclosures. Graduated PCOM in 1996 In private practice since 1999 Board Certified in FP since 1999 Program Director of FP residency at Lower Bucks Hospital in Bristol, PA
More informationADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP
ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP Page 1 1. In what year did the possession and transfer of cannabis for recreational use become illegal in the United States? A. 1937 B. 1941 C. 1933 2.
More informationABSTRACT BOOK PLATFORM
ICNC-0262 Evaluation of efficacy, safety and workload of inpatient and outpatient initiation of the Ketogenic Diet in children (0-18 y) with refractory epilepsy IntroductionKetogenic Diet (KD) treatment
More informationCannabis: Rocky Mountain Highlights for Health Care Providers
Cannabis: Rocky Mountain Highlights for Health Care Providers HASHing It Out: Overview of Medical Uses for Marijuana Skaggs School of Pharmacy Webinar Series Laura Borgelt, PharmD, FCCP, BCPS Associate
More informationDrug Class Update with New Drug Evaluations: Antiepileptics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationCannabis, Cannabidiol, and Epilepsy
Cannabis, Cannabidiol, and Epilepsy Clinical Considerations and Practical Applications A new frontier brings new questions and old dilemmas. By Adrian L. Turner, PharmD and M. Scott Perry, MD Background
More informationGW Pharmaceuticals plc. June 2016
GW Pharmaceuticals plc June 2016 Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs and assumptions and on information
More informationTHE COMPLETE CBD GUIDE
THE COMPLETE CBD GUIDE WHAT IS CBD (CANNABIDIOL)? 2 WHERE DOES CBD COME FROM? 3 HOW DOES CBD WORK IN THE BODY? 4 HOW MUCH CBD DO I TAKE? 5-6 CBD OIL VS. HEMP OIL 7 CBD NOT THC 8 THE BENEFITS OF CBD 9 PETS
More informationInvestor Presentation
Investor Presentation September 2018 2018 GW Pharmaceuticals plc All Rights Reserved Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA MINNESOTA ACADEMY OF PHYSICIAN ASSISTANTS MARCH 18, 2016 TOM ARNESON, MD, MPH MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program
More informationGlobal Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018
Global Legal Cannabis Market: Size, Trends & Forecasts (2018-2022) September 2018 Global Legal Cannabis Market: Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis
More informationLearning Objectives 1/8/2019. Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD. Disclosures. Outline. Take home messages
Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD CECILIA HILLARD, PHD DEPARTMENT OF PHARMACOLOGY NEUROSCIENCE RESEARCH CENTER Disclosures Member of the Scientific Advisory Board
More informationMARIJUANA & THE EFFECTS ON THE BRAIN
MARIJUANA & THE EFFECTS ON THE BRAIN Sheryl Ryan, MD Professor of Pediatrics Chief, Division of Adolescent Medicine, Penn State Health Hershey Medical Center DISCLOSURES I have no relevant financial relationships
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationMedical Marijuana: The Move to Schedule II
Medical Marijuana: The Move to Schedule II David Deitz, MD, PhD David Deitz & Associates Today s discussion Does medical marijuana actually treat anything? What are the workplace issues? What are the interactions
More informationEpilepsy in the developing brain
Epilepsy in the developing brain Dr Katherine Howell* Neurologist, Royal Children s Hospital Melbourne Clinician-Scientist Fellow, Murdoch Children s Research Institute Honorary Senior Fellow, University
More informationGeorgia Cannabidiol Study Frequently Asked Questions
Georgia Cannabidiol Study Frequently Asked Questions 1. Why was the Georgia Cannabidiol Study initiated? In January 2014, Representative Allen Peake visited with Haleigh Cox, a 4-year-old girl with severe
More informationTitle: CBD-enriched medical cannabis for intractable pediatric epilepsy. The current Israeli experience
Title: CBD-enriched medical cannabis for intractable pediatric epilepsy. The current Israeli experience Author: Michal Tzadok Shimrit Uliel-Siboni Ilan Linder Uri Kramer Orna Epstein Shai Menascu Andrea
More informationA GUIDE TO TALKING WITH YOUR DOCTOR ABOUT EPIDIOLEX
A GUIDE TO TALKING WITH YOUR DOCTOR ABOUT EPIDIOLEX You are encouraged to have an open conversation with your doctor about your treatment goals and current medicines. It is important in determining if
More informationChild Neurology. The Plural. of anecdote. is not evidence. University of Texas Health Science Center at San Antonio
Child Neurology Management of Seizure Disorders The stated goal of advocacy groups for patients with seizures, is to have the patient seizure free. S W Atkinson, MD Management of When to pharmacologically
More informationMedicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system
Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationFrom Opioid Replacement to Managing Chronic Pain: What is CBD?
From Opioid Replacement to Managing Chronic Pain: What is CBD? Kalev Freeman, MD PhD Assistant Professor of Surgery and Pharmacology, University of Vermont Laura Mann Integrative Healthcare Lecture Series
More informationThe epilepsies: pharmacological treatment by epilepsy syndrome
The epilepsies: pharmacological treatment by epilepsy syndrome This table provides a summary reference guide to pharmacological treatment. Anti-epileptic drug (AED) options by epilepsy syndrome Childhood
More informationAdaptive Enrichment Population Design Rare Epileptic Syndromes. Joanna Segieth, PhD Clinical Science Takeda
Adaptive Enrichment Population Design Rare Epileptic Syndromes Joanna Segieth, PhD Clinical Science Takeda Introduction Main features: Found in oncology study settings with potential for other therapeutic
More informationRecent trends in medical cannabis use in Canada
Recent trends in medical cannabis use in Canada Paul Grootendorst Faculty of Pharmacy, University of Toronto Department of Economics, McMaster University Cannabis therapeutic effects Cannabis has been
More informationMedical Cannabis. Christine Yoshioka, NP
Medical Cannabis Christine Yoshioka, NP Objectives Brief history of Cannabis in cultures Review of the Endocanabinoid system Exogenous cannabis Medical research involving cannabis and federal restrictions
More informationWHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts
More informationFebrile seizures. Olivier Dulac. Hôpital Necker-Enfants Malades, Université Paris V, INSERM U663
Febrile seizures Olivier Dulac Hôpital Necker-Enfants Malades, Université Paris V, INSERM U663 olivier.dulac@nck.aphp.fr Definition Seizures precipitated by fever that is not due to an intracranial infection
More informationCannabidiol (CBD) Basis for the Recommendation to Place in Schedule V of the CSA B. Evaluating CBD Under the Eight Factors This section presents the current scientific and medical information about CBD
More informationI would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people
I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people Introduction to the Cannabinoid System And Medical Use Dr Alia Norman Radiation Oncologist Cannabinoid
More informationUpdate in Pediatric Epilepsy
Update in Pediatric Epilepsy Cherie Herren, MD Assistant Professor OUHSC, Department of Neurology September 20, 2018 Disclosures None Objectives 1. Identify common pediatric epilepsy syndromes 2. Describe
More informationClinical Challenges and Political Uncertainty
Clinical Challenges and Political Uncertainty John Gaitanis, M.D. April 10 th, 2017 Commercial Support This activity does not have any commercial support 3 NEW THERAPY FOR AN INTRACTABLE CONDITION 4 New
More informationJP Morgan. January 2019
JP Morgan January 2019 Disclaimer THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E
More information2. Area of the brain affected by the seizures.
Learning Through Storms When discussing learning, we sometimes refer to cognition, or one s ability to think, learn and use information. Seizures can impact cognition, learning and behaviour in a variety
More informationDravet syndrome : Clinical presentation, genetic investigation and anti-seizure medication. Bradley Osterman MD, FRCPC, CSCN
Dravet syndrome : Clinical presentation, genetic investigation and anti-seizure medication Bradley Osterman MD, FRCPC, CSCN Objectives Learn about the typical early clinical presentation of Dravet syndrome
More informationMEDICAL CANNABIS IN MINNESOTA
MEDICAL CANNABIS IN MINNESOTA EPILEPSY & SEIZURES WELLNESS EXPO APRIL 16, 2016 MICHELLE LARSON, MPA MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program State
More informationSeizure medications An overview
Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at
More informationSECTION V: EMPLOYEES POLICY 5375 MEDICAL MARIJUANA, HEMP & CANNABIDIOL (CBD)
Regardless of a student, employee, parent or any individual s status as a medical marijuana license holder, marijuana is not allowed on the premises of the district or in any school vehicle or in any personal
More informationConsumer Information Cannabis (Marihuana, marijuana)
Consumer Information Cannabis (Marihuana, marijuana) The courts in Canada have ruled that the federal government must provide reasonable access to a legal source of marijuana for medical purposes. The
More informationEpilepsy management What, when and how?
Epilepsy management What, when and how? J Helen Cross UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, & National Centre for Young People with Epilepsy, Lingfield, UK What
More informationACTH therapy for generalized seizures other than spasms
Seizure (2006) 15, 469 475 www.elsevier.com/locate/yseiz ACTH therapy for generalized seizures other than spasms Akihisa Okumura a,b, *, Takeshi Tsuji b, Toru Kato b, Jun Natsume b, Tamiko Negoro b, Kazuyoshi
More informationNo relevant disclosures
No relevant disclosures - Epileptic Encephalopathy (EE): Epileptic activity itself contributes to cognitive and behavioural impairments - Developmental and Epileptic Encephalopathy (DEE): Impairments occur
More informationMedical Marijuana A Primer for Pharmacists
Medical Marijuana A Primer for Pharmacists Emory S. Martin, PharmD FASHP Texas Society of Health System Pharmacists Learning Objectives Recognize key components of the endocannabinoid system Identify possible
More informationMARIJUANA AND THE HEART. Katrinka Kip, MD Northern Nevada Heart Conference April 21, 2018
MARIJUANA AND THE HEART Katrinka Kip, MD Northern Nevada Heart Conference April 21, 2018 BEANS, BEANS ARE GOOD FOR YOUR HEART.. (The more you eat, the more you.) But what about marijuana? A DAD CALLED..
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_epilepsy 1/28/14 10/2017 10/2018 10/2017 Description of Procedure or Service Description
More informationCannabis and cannabinoids for medicinal purposes
Cannabis and cannabinoids for medicinal purposes International Evidence and Evidence for Practice in Australia Michael Farrell Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Megan Weir, Suzi Neilsen,
More informationRetrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients
Acta neurol. belg., 2000, 100, 171-176 Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients J. THIJS, H. VERHELST,
More informationMarijuana and the Liver. Lauren Myers MMsc, PA-C
Marijuana and the Liver Lauren Myers MMsc, PA-C Disclosures 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose. 2. The planners, Atif Zaman, MD, MPH have
More information